Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Development of 17 microsatellite markers in the federally endangered species Liatris helleri (Asteraceae).

Clark LC, Gaglianese-Woody MR, Estep MC.

Appl Plant Sci. 2019 May 17;7(7):e01250. doi: 10.1002/aps3.1250. eCollection 2019 Jul.

2.

Elucidating emotional closeness within the Theory of Health-Related Family Quality of Life: evidence from breast cancer survivors.

Elise Radina M, Deer BL, Herriman RA, Jagpal A, Dodd MM, Kawamura KL, Clark LC.

BMC Res Notes. 2019 Jun 3;12(1):312. doi: 10.1186/s13104-019-4354-5.

3.

Improving performance by anchoring movement and "nerves".

Iso-Ahola SE, Dotson CO, Jagodinsky AE, Clark LC, Smallwood LL, Wilburn C, Weimar WH, Miller MW.

Hum Mov Sci. 2016 Oct;49:239-47. doi: 10.1016/j.humov.2016.07.008. Epub 2016 Jul 25.

PMID:
27459587
4.

Caenorhabditis microbiota: worm guts get populated.

Clark LC, Hodgkin J.

BMC Biol. 2016 May 9;14:37. doi: 10.1186/s12915-016-0260-7.

6.

Worm-stars and half-worms: Novel dangers and novel defense.

Hodgkin J, Clark LC, Gravato-Nobre MJ.

Worm. 2014 Jan 31;3:e27939. doi: 10.4161/worm.27939. eCollection 2014.

7.

Two Leucobacter strains exert complementary virulence on Caenorhabditis including death by worm-star formation.

Hodgkin J, FĂ©lix MA, Clark LC, Stroud D, Gravato-Nobre MJ.

Curr Biol. 2013 Nov 4;23(21):2157-61. doi: 10.1016/j.cub.2013.08.060. Epub 2013 Oct 24.

8.

Commensals, probiotics and pathogens in the Caenorhabditis elegans model.

Clark LC, Hodgkin J.

Cell Microbiol. 2014 Jan;16(1):27-38. doi: 10.1111/cmi.12234. Epub 2013 Nov 15. Review.

PMID:
24168639
9.

Mammalian cell entry genes in Streptomyces may provide clues to the evolution of bacterial virulence.

Clark LC, Seipke RF, Prieto P, Willemse J, van Wezel GP, Hutchings MI, Hoskisson PA.

Sci Rep. 2013;3:1109. doi: 10.1038/srep01109. Epub 2013 Jan 23.

10.

Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer.

Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, Thompson PA, Slate E, Hsu CH, Dalkin BL, Sindhwani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP.

Prostate. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10.

11.

Duplication and evolution of devA-like genes in Streptomyces has resulted in distinct developmental roles.

Clark LC, Hoskisson PA.

PLoS One. 2011;6(10):e25049. doi: 10.1371/journal.pone.0025049. Epub 2011 Oct 5.

12.

Dose-dependent effects of selenized yeast on total selenium levels in prostatic tissue of men with prostate cancer.

Algotar AM, Stratton MS, Xu MJ, Dalkin BL, Nagle RB, Hsu CH, Ahmann FR, Clark LC, Stratton SP.

Nutr Cancer. 2011;63(1):1-5. doi: 10.1080/01635581.2010.516476. No abstract available.

13.

Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer.

Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR.

Cancer Prev Res (Phila). 2010 Aug;3(8):1035-43. doi: 10.1158/1940-6207.CAPR-09-0143. Epub 2010 Jul 20.

14.

The nutritional prevention of cancer: 400 mcg per day selenium treatment.

Reid ME, Duffield-Lillico AJ, Slate E, Natarajan N, Turnbull B, Jacobs E, Combs GF Jr, Alberts DS, Clark LC, Marshall JR.

Nutr Cancer. 2008;60(2):155-63. doi: 10.1080/01635580701684856.

PMID:
18444146
15.

Troubleshooting sterilization.

Clark LC.

Mater Manag Health Care. 2007 Mar;16(3):42, 44. No abstract available.

PMID:
17439060
16.

SLE in a United States-Mexico border community.

Walsh BT, Pope C, Reid M, Gall EP, Yocum DE, Clark LC.

J Clin Rheumatol. 2001 Feb;7(1):3-9.

PMID:
17039079
17.

Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial.

Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, Farinaro E, Clark LC, Reid ME.

Am J Epidemiol. 2006 Apr 15;163(8):694-9. Epub 2006 Feb 22.

PMID:
16495471
18.

Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas.

Saba SR, Garces AH, Clark LC, Soto J, Gower WR Jr, Vesely DL.

J Histochem Cytochem. 2005 Aug;53(8):989-95. Epub 2005 May 6.

PMID:
15879575
19.

A report of high-dose selenium supplementation: response and toxicities.

Reid ME, Stratton MS, Lillico AJ, Fakih M, Natarajan R, Clark LC, Marshall JR.

J Trace Elem Med Biol. 2004;18(1):69-74.

PMID:
15487766
20.

Novel therapeutic approach for cancer using four cardiovascular hormones.

Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J, Gower WR Jr.

Eur J Clin Invest. 2004 Oct;34(10):674-82.

PMID:
15473892
21.

Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial.

Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group.

J Natl Cancer Inst. 2003 Oct 1;95(19):1477-81.

PMID:
14519754
22.

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial.

Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group.

BJU Int. 2003 May;91(7):608-12.

23.

Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial.

Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, Marshall JR.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1285-91.

24.

Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial.

Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, Marshall JR, Clark LC.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):630-9.

25.

An analysis of cancer prevention by selenium.

Combs GF Jr, Clark LC, Turnbull BW.

Biofactors. 2001;14(1-4):153-9. Review.

PMID:
11568452
27.

Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.

Clark LC, Davis CW.

Am J Health Syst Pharm. 2000 Nov 15;57 Suppl 3:S10-3.

PMID:
11098314
28.

The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts.

Baines AT, Holubec H, Basye JL, Thorne P, Bhattacharyya AK, Spallholz J, Shriver B, Cui H, Roe D, Clark LC, Earnest DL, Nelson MA.

Cancer Lett. 2000 Nov 28;160(2):193-8.

PMID:
11053649
29.

A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations.

Lin H, McCulloch CE, Turnbull BW, Slate EH, Clark LC.

Stat Med. 2000 May 30;19(10):1303-18.

PMID:
10814979
30.

Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days.

Clark LC, Farghaly H, Saba SR, Vesely DL.

Am J Physiol Heart Circ Physiol. 2000 May;278(5):H1555-64.

31.

Effect of Digoxin on Ventricular Remodeling and Responsiveness of beta-Adrenoceptors in Chronic Volume Overload.

Sullebarger JT, D'Ambra PM, Clark LC, Thanikarry L, Fontanet HL.

J Cardiovasc Pharmacol Ther. 1998 Oct;3(4):281-290.

PMID:
10684510
32.

Interdisciplinary adolescent health training in supervised dietetic practice programs across the southern United States.

Hergenroeder AC, Morrow SR, Clark LC.

J Am Diet Assoc. 1999 Nov;99(11):1450-2. No abstract available.

PMID:
10570687
33.
34.

Elevated atrial natriuretic peptides and early renal failure in type 2 diabetic Goto-Kakizaki rats.

Vesely DL, Gower WR Jr, Dietz JR, Overton RM, Clark LC, Antwi EK, Farese RV.

Metabolism. 1999 Jun;48(6):771-8.

PMID:
10381153
35.

Selenium and prostate cancer prevention.

Nelson MA, Porterfield BW, Jacobs ET, Clark LC.

Semin Urol Oncol. 1999 May;17(2):91-6. Review.

PMID:
10332922
36.

Environmental selenium and cancer: risk or protection?

Clark LC, Jacobs ET.

Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):847-8; discussion 851-2. Review. No abstract available.

37.

Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.

Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J.

Br J Urol. 1998 May;81(5):730-4.

PMID:
9634050
38.

Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines.

Redman C, Scott JA, Baines AT, Basye JL, Clark LC, Calley C, Roe D, Payne CM, Nelson MA.

Cancer Lett. 1998 Mar 13;125(1-2):103-10.

PMID:
9566703
39.

Langerhans cell histiocytosis with orbital involvement.

Kramer TR, Noecker RJ, Miller JM, Clark LC.

Am J Ophthalmol. 1997 Dec;124(6):814-24.

PMID:
9402828
40.

Reduction of cancer mortality and incidence by selenium supplementation.

Combs GF Jr, Clark LC, Turnbull BW.

Med Klin (Munich). 1997 Sep 15;92 Suppl 3:42-5.

PMID:
9342915
41.

Reduction of cancer risk with an oral supplement of selenium.

Combs GF Jr, Clark LC, Turnbull BW.

Biomed Environ Sci. 1997 Sep;10(2-3):227-34.

PMID:
9315315
42.

Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells.

Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, Nelson MA.

Carcinogenesis. 1997 Jun;18(6):1195-202.

PMID:
9214603
43.

Regression models for recurrent event data: parametric random effects models with measurement error.

Turnbull BW, Jiang W, Clark LC.

Stat Med. 1997 Apr 30;16(8):853-64.

PMID:
9160484
44.

Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.

Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR.

JAMA. 1996 Dec 25;276(24):1957-63. Erratum in: JAMA 1997 May 21;277(19):1520.

PMID:
8971064
45.

A computer program for sample size and power calculations in the design of multi-arm and factorial clinical trials with survival time endpoints.

Natarajan R, Turnbull BW, Slate EH, Clark LC.

Comput Methods Programs Biomed. 1996 Mar;49(2):137-47.

PMID:
8735021
46.

Prolonged studies of perfluorocarbon associated gas exchange.

Clark LC Jr.

Crit Care Med. 1996 Mar;24(3):548-9. No abstract available.

PMID:
8625649
47.

Liquid ventilation in premature lambs: uptake, biodistribution and elimination of perfluorodecalin liquid.

Shaffer TH, Wolfson MR, Greenspan JS, Hoffman RE, Davis SL, Clark LC Jr.

Reprod Fertil Dev. 1996;8(3):409-16.

PMID:
8795104
48.

Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis.

Manzone H, Billings PC, Cummings WN, Feldman R, Clark LC, Odell CS, Horan AM, Atiba JO, Meyskens FL, Kennedy AR.

Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):521-7.

49.

Regression of cardiac hypertrophy after closing an aortocaval fistula in rats.

Gerdes AM, Clark LC, Capasso JM.

Am J Physiol. 1995 Jun;268(6 Pt 2):H2345-51.

PMID:
7611486
50.

Selenium and cancer: risk or protection?

Clark LC, Alberts DS.

J Natl Cancer Inst. 1995 Apr 5;87(7):473-5. No abstract available.

PMID:
7707429

Supplemental Content

Loading ...
Support Center